Humacyte Reports Q1 2026 Earnings, Announces Leadership Changes and Workforce Restructuring
Humacyte (HUMA) released its first-quarter 2026 earnings transcript, highlighting progress in the commercial launch of its Symvess vascular graft. Q1 sales reached $0.5 million, up from $0.1 million in the same period last year. To accelerate global expansion, the company appointed James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer. Internationally, Humacyte submitted a marketing authorization application to Israel’s Ministry of Health and secured a $1.475 million purchase commitment from Saudi Arabia, alongside ongoing joint venture negotiations. The U.S. Department of Defense also committed funding for evaluating Symvess for battlefield trauma care. Concurrently, Humacyte implemented a workforce restructuring in May 2026, reducing headcount by approximately 25% (45 employees) to optimize expenses while retaining key resources. Core corporate goals for the year include advancing Symvess commercialization, completing the V012 Phase III trial for dialysis access, filing a supplemental BLA with the FDA, and initiating a first-in-human study for its coronary tissue-engineered vessel.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection